GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Retained Earnings

Fusion Antibodies (LSE:FAB) Retained Earnings : £-8.91 Mil (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Fusion Antibodies's retained earnings for the quarter that ended in Sep. 2023 was £-8.91 Mil.

Fusion Antibodies's quarterly retained earnings declined from Sep. 2022 (£-6.12 Mil) to Mar. 2023 (£-7.56 Mil) and declined from Mar. 2023 (£-7.56 Mil) to Sep. 2023 (£-8.91 Mil).

Fusion Antibodies's annual retained earnings declined from Mar. 2021 (£-3.82 Mil) to Mar. 2022 (£-5.00 Mil) and declined from Mar. 2022 (£-5.00 Mil) to Mar. 2023 (£-7.56 Mil).


Fusion Antibodies Retained Earnings Historical Data

The historical data trend for Fusion Antibodies's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Retained Earnings Chart

Fusion Antibodies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only -0.40 -0.94 -3.82 -5.00 -7.56

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.40 -5.00 -6.12 -7.56 -8.91

Fusion Antibodies Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Fusion Antibodies  (LSE:FAB) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Fusion Antibodies (LSE:FAB) Business Description

Traded in Other Exchanges
N/A
Address
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 10-21-2022